Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)
Saudi Arabia · Delayed Price · Currency is SAR 29.20
-0.44 (-1.48%)
At close: Feb 11, 2026
TADAWUL:2070 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,686 | 1,682 | 1,655 | 1,422 | 1,460 | 1,555 | |
Revenue Growth (YoY) | 3.36% | 1.60% | 16.43% | -2.60% | -6.14% | 4.60% |
Cost of Revenue | 887.15 | 865.95 | 965.8 | 864.5 | 846.73 | 869.96 |
Gross Profit | 798.99 | 816.05 | 689.64 | 557.31 | 613.05 | 685.32 |
Selling, General & Admin | 543.07 | 592.49 | 615.47 | 620.63 | 551.26 | 530.74 |
Research & Development | 74.17 | 76.39 | 41.8 | 42.65 | 29.07 | 20.35 |
Other Operating Expenses | -43.13 | -4.44 | -69.39 | -7.93 | 13.74 | -10.98 |
Operating Expenses | 611.18 | 701.49 | 629.92 | 665.39 | 580.22 | 541.58 |
Operating Income | 187.81 | 114.56 | 59.72 | -108.08 | 32.83 | 143.75 |
Interest Expense | -97.95 | -86.78 | -63.51 | -34.33 | -31.4 | -33.61 |
Interest & Investment Income | 8.16 | 7.66 | 10.59 | - | - | 7 |
Earnings From Equity Investments | 28.74 | 22.73 | 20 | 20.44 | 11.41 | 38.21 |
Currency Exchange Gain (Loss) | 2.16 | -10.16 | -4.32 | -14.38 | 15.03 | -0.47 |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | -3.17 | - | -1.49 | 0.3 |
EBT Excluding Unusual Items | 128.93 | 48.02 | 19.3 | -136.35 | 26.38 | 155.18 |
Gain (Loss) on Sale of Investments | - | - | - | 3.63 | 7.81 | 3.52 |
Gain (Loss) on Sale of Assets | 18.94 | 18.94 | 6.38 | 0.14 | -0.45 | - |
Legal Settlements | -3.87 | 5.05 | -20.47 | - | - | - |
Pretax Income | 169.38 | 72.01 | 5.21 | -132.59 | 33.73 | 158.7 |
Income Tax Expense | 31.16 | 40.17 | 45.26 | 25.9 | 12.35 | 43.9 |
Earnings From Continuing Operations | 138.22 | 31.84 | -40.05 | -158.48 | 21.38 | 114.81 |
Earnings From Discontinued Operations | - | - | - | -12.75 | -3.28 | -5.26 |
Net Income to Company | 138.22 | 31.84 | -40.05 | -171.23 | 18.1 | 109.54 |
Minority Interest in Earnings | -9.49 | -7.31 | -10.68 | 6.1 | 8.35 | 15.25 |
Net Income | 128.73 | 24.54 | -50.73 | -165.14 | 26.45 | 124.79 |
Net Income to Common | 128.73 | 24.54 | -50.73 | -165.14 | 26.45 | 124.79 |
Net Income Growth | - | - | - | - | -78.80% | - |
Shares Outstanding (Basic) | 119 | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 119 | 120 | 120 | 120 | 120 | 120 |
Shares Change (YoY) | -0.18% | -0.08% | -0.31% | - | - | - |
EPS (Basic) | 1.08 | 0.21 | -0.42 | -1.38 | 0.22 | 1.04 |
EPS (Diluted) | 1.08 | 0.21 | -0.42 | -1.38 | 0.22 | 1.04 |
EPS Growth | - | - | - | - | -78.80% | - |
Free Cash Flow | 119.05 | -402.23 | -95.92 | -177.51 | 10.47 | -155.02 |
Free Cash Flow Per Share | 1.00 | -3.37 | -0.80 | -1.48 | 0.09 | -1.29 |
Dividend Per Share | - | - | - | - | 0.600 | 1.000 |
Dividend Growth | - | - | - | - | -40.00% | - |
Gross Margin | 47.39% | 48.52% | 41.66% | 39.20% | 42.00% | 44.06% |
Operating Margin | 11.14% | 6.81% | 3.61% | -7.60% | 2.25% | 9.24% |
Profit Margin | 7.63% | 1.46% | -3.06% | -11.61% | 1.81% | 8.02% |
Free Cash Flow Margin | 7.06% | -23.91% | -5.79% | -12.48% | 0.72% | -9.97% |
EBITDA | 283 | 189.52 | 131.34 | -28.21 | 112.57 | 222.17 |
EBITDA Margin | 16.78% | 11.27% | 7.93% | -1.98% | 7.71% | 14.29% |
D&A For EBITDA | 95.19 | 74.96 | 71.62 | 79.87 | 79.74 | 78.43 |
EBIT | 187.81 | 114.56 | 59.72 | -108.08 | 32.83 | 143.75 |
EBIT Margin | 11.14% | 6.81% | 3.61% | -7.60% | 2.25% | 9.24% |
Effective Tax Rate | 18.40% | 55.78% | 868.21% | - | 36.60% | 27.66% |
Advertising Expenses | - | 33.2 | 56.75 | 41.89 | 40.43 | 35.98 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.